Suraksha Diagnostic cools growth targets to 15% for FY27
Management pivots on performance metrics while shifting toward public-private partnerships, drawing scrutiny.
What's new
- Revenue growth target drops to 15% from 22.5% in FY26.
- Management targets a 33% EBITDA margin, up from 31.5% last year.
- Company plans to open 14 new centres with ₹70 cr in capex.
Why it matters
The company’s sudden dismissal of patient volume as a core metric leaves shareholders guessing about how it tracks success. Re-entering public-private partnerships after previous denials suggests a lack of clarity in long-term goals.
What we're watching
- Whether the new centres hit the targeted 33% EBITDA margin.
- Future profitability disclosures on public-private contracts.
- Management’s rationale for ignoring patient volume in upcoming results.
The full read
Suraksha Diagnostic enters FY27 with a more conservative outlook. Management projected 15% revenue growth for the year, a drop from the 22.5% expansion recorded in FY26. To hit their 33% EBITDA margin goal, the firm must lift returns by 150 basis points from last year’s 31.5% print. A ₹70 crore capex plan to build 14 new centres is the engine for this goal.
Then the mood soured.
Management dismissed patient volume as a primary performance metric, despite using it as a key yardstick in previous quarters. The company also signaled an appetite for public-private partnership contracts, contradicting earlier statements that it would avoid such agreements. The market is left with a firm that is growing slower and changing its playbook mid-stream. It is an uncomfortable shift.